710272-54-1

Usage

Uses

Used in Pharmaceutical Research:
1-(2-Chloroethyl)-4-(4-nitrophenyl)piperazine is used as a potential antitumor agent for its demonstrated cytotoxic effects on various cancer cell lines. Studies have shown that CEP can inhibit cancer cell growth, making it a valuable compound in the development of novel cancer treatments.
Used in Overcoming Multidrug Resistance:
1-(2-Chloroethyl)-4-(4-nitrophenyl)piperazine is used as a compound to potentially overcome multidrug resistance in cancer cells. This resistance is a significant challenge in cancer treatment, and CEP's ability to counteract it could lead to more effective therapies for patients with drug-resistant cancers.
Used in Anti-inflammatory and Analgesic Applications:
CEP is also being explored for its anti-inflammatory and analgesic properties, which could make it useful in the development of new medications for conditions involving inflammation and pain. Its versatility as a chemical compound positions it as a candidate for various applications in the pharmaceutical industry.

Upstream product

• 6269-89-2 1-(4-Nitrophenyl)piperazine 
• 5521-38-0 2-(4-(4-nitrophenyl)piperazin-1-yl)ethan-1-ol 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 837421-36-0 1-((2-ethylamino)ethyl)-4-(4-nitrophenyl)piperazine hydrochloride 
• 837421-35-9 1-(2-(ethylamino)ethyl)-4-(4-nitrophenyl)piperazine 
• 837421-32-6 1-(2-azidoethyl)-4-(4-nitrophenyl)piperazine 

Relevant academic research and scientific papers

Novel aryl piperazines for alleviation of ‘andropause’ associated prostatic disorders and depression

A series of seventeen piperazine derivatives have been synthesized and biologically evaluated for the management of andropause-associated prostatic disorders and depression. Five compounds 16, 19, 20, 21 and 22 significantly inhibited proliferation of and

2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES

The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula (1) and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.

Microwave-assisted solvent-free synthesis of 3-[(4-substituted piperazin-1-yl)alkyl] imidazo[2,1-b][1,3]benzothiazol-2(3H)-ones as serotonin3 (5-HT3) receptor antagonists

A series of novel 3-[(4-substituted piperazin-1-yl)alkyl]imidazo[2,1-b][1, 3]benzothiazol-2(3H)-ones were prepared by microwave irradiation using alumina as solid support and also by a conventional method. The compounds were characterized by spectral data and the purity was ascertained by microanalysis. The synthesized compounds were evaluated for 5-hydroxytryptamine3 antagonisms in a longitudinal muscle-myenteric plexus preparation from guinea pig ileum against the 5-hydroxytryptamine3 agonist, 2-methyl-5-hydroxytryptamine. Among the test compounds, 3-[2-(4-methylpiperazin- 1-yl)ethyl]imidazo[2,1-6][1,3]benzothiazol-2(3H)-one (3b) showed most favorable 5-hydroxytryptamine3 antagonism (pA2 6.7) in the isolated guinea pig ileum.